Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05654883
Other study ID # 22-01338
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 11, 2022
Est. completion date December 31, 2028

Study information

Verified date January 2024
Source NYU Langone Health
Contact Mark J. Mulligan, MD
Phone 877-919-2822
Email Mark.mulligan@nyulangone.org
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this study is to assess the immune response, tolerance, and safety of the low-dose intradermal (forearm) mpox vaccine in people who are HIV+ compared to people who are HIV-, and compared to the standard-dose subcutaneous (upper arm) vaccine. The resulting data will fill knowledge gaps, inform public health practices, and address community concerns about the absence of data for low-dose intradermal mpox vaccinations in people living with HIV.


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date December 31, 2028
Est. primary completion date December 31, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: 1. Must be able to understand and sign the Informed Consent Form (ICF) 2. =18 years of age a. Including breastfeeding and pregnant people 3. Must have one or the other of criteria a and b, or can have both: 1. Planning receipt of (in the next 30 days) or have received the mpox vaccine, and/or 2. people with recent mpox infection who are out of isolation (=30 days after symptom onset) 4. Willingness and ability to participate in all study procedures Exclusion Criteria: 1. Known clinically significant anemia (i.e., Hb < 10 g/dL) 2. Contraindication to phlebotomy based on investigator judgement; e.g., anti-coagulation therapy with history of phlebotomy complications, or clinically significant thrombocytopenia 3. Any condition that, in the opinion of the Investigator, would make study participation unsafe for the individual or would interfere with the objectives of the study

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States NYU Langone Health New York New York

Sponsors (1)

Lead Sponsor Collaborator
NYU Langone Health

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Geometric Mean Titer (GMT) of Serum Neutralization of Mpox Virus approximately 14 Days After Second Vaccination Measured using live-virus mpox neutralization assay, plaque reduction neutralization assay (PRNT). Day 14 Post-Second Vaccination
Primary Number of Solicited Adverse Events through Day 14 Post-Vaccinations Participants will complete a 14-day diary recording solicited adverse events following each vaccination. Day 14 Post-Vaccination
Primary Number of Adverse Events that Occur within 28 Days After Final Vaccination Day 28 Post-Final Vaccination
Secondary GMT of Mpox Virus-Specific Serum Immunoglobulin approximately 28 Days After First Vaccination Measured using enzyme-linked immunosorbent assay (ELISA). Day 28 Post-First Vaccination
Secondary GMT of Mpox Virus-Specific Serum Immunoglobulin approximately 56 Days After First Vaccination Measured using enzyme-linked immunosorbent assay (ELISA). Day 56 Post-First Vaccination
Secondary GMT of Mpox Virus-Specific Serum Immunoglobulin approximately 14 Days After Second Vaccination Measured using enzyme-linked immunosorbent assay (ELISA). Day 56 Post-Second Vaccination
Secondary GMT of Serum Neutralization of Mpox Virus approximately 28 Days After First Vaccination Measured using live-virus mpox neutralization assay, plaque reduction neutralization assay (PRNT). Day 28 Post-First Vaccination
Secondary GMT of Serum Neutralization of Mpox Virus approximately 56 Days After First Vaccination Measured using live-virus mpox neutralization assay, plaque reduction neutralization assay (PRNT). Day 56 Post-First Vaccination
See also
  Status Clinical Trial Phase
Recruiting NCT06162897 - Case Management Dyad N/A
Completed NCT03999411 - Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients Phase 4
Completed NCT02528773 - Efficacy of ART to Interrupt HIV Transmission Networks
Active, not recruiting NCT05454839 - Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
Recruiting NCT05322629 - Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women N/A
Completed NCT02579135 - Reducing HIV Risk Among Adolescents: Evaluating Project HEART N/A
Active, not recruiting NCT01790373 - Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence N/A
Not yet recruiting NCT06044792 - The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
Completed NCT04039217 - Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM Phase 4
Active, not recruiting NCT04519970 - Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK) N/A
Completed NCT04124536 - Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women N/A
Recruiting NCT05599581 - Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health N/A
Active, not recruiting NCT04588883 - Strengthening Families Living With HIV in Kenya N/A
Completed NCT02758093 - Speed of Processing Training in Adults With HIV N/A
Completed NCT02500446 - Dolutegravir Impact on Residual Replication Phase 4
Completed NCT03805451 - Life Steps for PrEP for Youth N/A
Active, not recruiting NCT03902431 - Translating the ABCS Into HIV Care N/A
Completed NCT00729391 - Women-Focused HIV Prevention in the Western Cape Phase 2/Phase 3
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Recruiting NCT03589040 - Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant Phase 2